Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretro... by Ross, LL, Walker, AS, Lou, Y, Tenorio, AR, Gibb, DM, Double, J, Gilks, C, McCoig, CC, Munderi, P, Musoro, G, Kityo, CM, Grosskurth, H, Hakim, J, Mugyenyi, PN, Cutrell, A, Perger, T, Shaefer, MS

Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status by Pett, SL, Spyer, M, Haddow, L, Nhema, R, Benjamin, L, Najjuka, G, Bilima, S, Daud, I, Musoro, G, Kitabalwa, J, Selemani, G, Kandie, S, Cornelius, KM, Katemba, C, Berkley, J, Hassan, A, Kityo, C, Hakim, J, Heyderman, R, Gibb, DM, Walker, AS

Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial by Post, F, Szubert, A, Prendergast, A, Johnston, V, Lyall, H, Fitzgerald, F, Musiime, V, Musoro, G, Chepkrorir, P, Agutu, C, Mallewa, J, Rajapakse, C, Wilkes, H, Hakim, J, Mugyenyi, P, Walker, A, Gibb, D, Pett, S, on behalf of the REALITY trial team

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa by Hakim, J, Musiime, V, Szubert, A, Mallewa, J, Siika, A, Agutu, C, Walker, S, Pett, S, Bwakura-Dangarembizi, M, Lugemwa, A, Kaunda, S, Karoney, M, Musoro, G, Kabahenda, S, Nathoo, K, Maitland, K, Griffiths, A, Thomason, M, Kityo, C, Mugyenyi, P, Prendergast, A, Walker, A, Gibb, D

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial by Kityo, C, Szubert, A, Siika, A, Heydermann, R, Bwakura-Dangarembizi, M, Lugemwa, A, Mwaringa, S, Griffiths, A, Nkanya, I, Kabahenda, S, Wachira, S, Musoro, G, Rajapakse, C, Etyang, T, Abach, J, Spyer, M, Wavamunno, P, Nyondo-Mipanda, L, Chidziva, E, Nathoo, K, Klein, N, Hakim, J, Gibb, D, Walker, A, Pett, S